Established Pharmaceuticals sales increased almost 8% on an organic basis (6.9% reported), with double-digit increases in several countries across Asia, Latin America and the Middle East. Strong demand for Ensure and Glucerna fueled more than 6% organic growth in Adult Nutrition (6.1% reported), leading overall Nutrition sales performance.
Adjusted diluted earnings per share (EPS) was $1.26, reflecting double-digit growth compared to the prior year (GAAP diluted EPS was $1.01). We narrowed our full-year 2025 adjusted diluted EPS guidance3 range to $5.10 to $5.20, which reflects double-digit growth at the midpoint of $5.15. Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0% or 6.0% to 7.0%, when including COVID-19 testing-related sales.
During the second quarter, we continued to advance our pipeline with purpose, delivering on our mission to broaden the impact of our breakthrough technologies. Notable milestones include:
Completed enrollment in the U.S. IDE trial for the TactiFlex™ Duo Pulsed Field Ablation (PFA) System—which is being evaluated for the treatment of patients with heart rhythm disorders such as atrial fibrillation.Announced clinical data from the AVEIR™ Conduction System Pacing (CSP) feasibility study—the world’s first evaluation of a leadless pacemaker capable of delivering conduction pacing that closely mimics the heart’s natural rhythm.Received FDA approval for our Tendyne™ transcatheter mitral valve replacement (TMVR) system—the first device of its kind designed to replace the mitral valve without the need for open-heart surgery.Initiated development of a new cardiovascular device manufacturing facility—located in the state of Georgia to be completed by 2028.
For full financial data and reconciliation of non-GAAP measures, you can read Abbott’s full press release.
For more information, view a summary of Abbott’s earnings highlights and download it here.